BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge - 26 Fun Urban areas For Seniors To Travel
- 3‘Inoculation’ helps people spot political deepfakes, study finds
- 4A Manual for Nations with Extraordinary Food
- 5CDC changes kids' vaccine schedule, removing universal recommendation for some shots
- Tzrifin base exhibition reveals Hamas and Hezbollah arms, showing structure behind attacks
- The Response to Independence from the rat race: Methodologies for Creating Financial momentum
- Rescuers give up hope for the humpback whale stranded in the Baltic Sea
- Pick Your Favored kind of soup
- CDC studies show value of nationwide wastewater disease surveillance, as potential funding cut looms
- Car Investigation: A Survey of \Past the Outside\ Car
- Turning into a Sharp Financial backer: Individual budget Wins
- China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight
- The Best Computer games for Multiplayer Fun
